CN100548993C - 缬沙坦的盐 - Google Patents

缬沙坦的盐 Download PDF

Info

Publication number
CN100548993C
CN100548993C CNB038032600A CN03803260A CN100548993C CN 100548993 C CN100548993 C CN 100548993C CN B038032600 A CNB038032600 A CN B038032600A CN 03803260 A CN03803260 A CN 03803260A CN 100548993 C CN100548993 C CN 100548993C
Authority
CN
China
Prior art keywords
valsartan
salt
calcium salt
water
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB038032600A
Other languages
English (en)
Chinese (zh)
Other versions
CN1628106A (zh
Inventor
E·马蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1628106A publication Critical patent/CN1628106A/zh
Application granted granted Critical
Publication of CN100548993C publication Critical patent/CN100548993C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
CNB038032600A 2002-02-04 2003-02-03 缬沙坦的盐 Expired - Lifetime CN100548993C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35419902P 2002-02-04 2002-02-04
US60/354,199 2002-02-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910167071XA Division CN101633646B (zh) 2002-02-04 2003-02-03 缬沙坦的盐

Publications (2)

Publication Number Publication Date
CN1628106A CN1628106A (zh) 2005-06-15
CN100548993C true CN100548993C (zh) 2009-10-14

Family

ID=27734333

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB038032600A Expired - Lifetime CN100548993C (zh) 2002-02-04 2003-02-03 缬沙坦的盐
CN200910167071XA Expired - Lifetime CN101633646B (zh) 2002-02-04 2003-02-03 缬沙坦的盐

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200910167071XA Expired - Lifetime CN101633646B (zh) 2002-02-04 2003-02-03 缬沙坦的盐

Country Status (17)

Country Link
US (3) US6869970B2 (enExample)
EP (1) EP1474402A1 (enExample)
JP (2) JP4895475B2 (enExample)
KR (3) KR20120054667A (enExample)
CN (2) CN100548993C (enExample)
AU (1) AU2003214054B2 (enExample)
BR (1) BR0307442A (enExample)
CA (2) CA2776902A1 (enExample)
CO (1) CO5611107A2 (enExample)
EC (1) ECSP045221A (enExample)
MX (1) MXPA04007525A (enExample)
NO (1) NO328155B1 (enExample)
NZ (1) NZ534560A (enExample)
PL (1) PL370481A1 (enExample)
RU (1) RU2004126862A (enExample)
WO (1) WO2003066606A1 (enExample)
ZA (1) ZA200405698B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
ATE409476T1 (de) * 2002-06-13 2008-10-15 Novartis Pharma Gmbh Calciumsalze von statinen aus indol
US20040242661A1 (en) * 2003-03-17 2004-12-02 Igor Rukhman Polymorphs of valsartan
AU2004238546A1 (en) * 2003-05-16 2004-11-25 Novartis Ag Pharmaceutical composition comprising valsartan
CN1882334A (zh) * 2003-11-14 2006-12-20 诺瓦提斯公司 用于治疗肾病综合征的at1－受体拮抗剂
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
DE502004002443D1 (de) * 2004-04-15 2007-02-08 Helm Ag Verfahren zur Herstellung von freifliessenden, pulverförmigen Valsartan-Adsorbaten
AR050043A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
KR20070074576A (ko) 2004-10-29 2007-07-12 코와 가부시키가이샤 사구체 질환 치료제
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2008035364A2 (en) * 2006-06-23 2008-03-27 Usv Limited Process for the preparation of micronized valsartan
PE20080991A1 (es) 2006-06-27 2008-09-05 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
PE20080907A1 (es) * 2006-08-31 2008-08-22 Novartis Ag Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan
US8071596B2 (en) 2007-01-12 2011-12-06 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
CN101396366B (zh) * 2007-09-25 2010-10-13 浙江华海药业股份有限公司 含缬沙坦的固体口服制剂及其制备方法
ES2336755B1 (es) * 2008-10-07 2011-01-21 Activery Biotech, S.L. Procedimiento para la preparacion de combinaciones de valsartan y simvastatina.
JP2011063518A (ja) * 2009-09-15 2011-03-31 Tohoku Univ Ａｒｂ及び／又はグリタゾン系血糖降下物質を含有するｏａｔｐ−ｒ遺伝子発現増強組成物
AR082435A1 (es) 2010-08-03 2012-12-05 Novartis Ag Valsartan altamente cristalino
CN103012301B (zh) * 2013-01-05 2015-06-17 江苏施美康药业股份有限公司 缬沙坦甲酯碱金属盐及其制备方法
DE102014004512A1 (de) * 2014-03-28 2015-10-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin Anorganisch-organische Hybridverbindung
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399578A (en) * 1990-02-19 1995-03-21 Ciba-Geigy Corp Acyl compounds
WO2002006253A1 (en) * 2000-07-19 2002-01-24 Novartis Ag Valsartan salts

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9707683A (es) * 1995-04-07 1997-12-31 Novartis Ag Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
ES2099031B1 (es) 1995-05-31 1997-12-01 Esteve Labor Dr Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
EE9900377A (et) * 1997-02-28 2000-04-17 Burstein Laboratories, Inc. Labor laserkettas
US6641886B1 (en) * 1999-03-23 2003-11-04 Flexplay Technologies, Inc. Directory read inhibitor for optical storage media
JP2001155346A (ja) * 1999-11-26 2001-06-08 Toshiba Corp 情報記録媒体、情報記録装置、情報記録方法、情報再生装置、情報再生方法
SK16372002A3 (sk) 2000-04-24 2003-04-01 Teva Pharmaceutical Industries Ltd. Zolpidem hemitartrát
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399578A (en) * 1990-02-19 1995-03-21 Ciba-Geigy Corp Acyl compounds
WO2002006253A1 (en) * 2000-07-19 2002-01-24 Novartis Ag Valsartan salts

Also Published As

Publication number Publication date
KR20110101257A (ko) 2011-09-15
AU2003214054B2 (en) 2007-08-16
CA2474424A1 (en) 2003-08-14
KR20040081178A (ko) 2004-09-20
CN1628106A (zh) 2005-06-15
NO20043660L (no) 2004-10-12
RU2004126862A (ru) 2005-06-27
ECSP045221A (es) 2004-09-28
BR0307442A (pt) 2005-01-04
EP1474402A1 (en) 2004-11-10
AU2003214054A1 (en) 2003-09-02
CN101633646A (zh) 2010-01-27
US20120022268A1 (en) 2012-01-26
CN101633646B (zh) 2012-08-29
HK1139681A1 (en) 2010-09-24
PL370481A1 (en) 2005-05-30
US8329919B2 (en) 2012-12-11
US6869970B2 (en) 2005-03-22
NZ534560A (en) 2007-05-31
NO328155B1 (no) 2009-12-21
JP5303370B2 (ja) 2013-10-02
CO5611107A2 (es) 2006-02-28
CA2776902A1 (en) 2003-08-14
US20050101652A1 (en) 2005-05-12
US20030171414A1 (en) 2003-09-11
WO2003066606A1 (en) 2003-08-14
JP2009235086A (ja) 2009-10-15
JP4895475B2 (ja) 2012-03-14
JP2005517696A (ja) 2005-06-16
ZA200405698B (en) 2006-05-31
MXPA04007525A (es) 2004-11-10
US8058301B2 (en) 2011-11-15
KR20120054667A (ko) 2012-05-30
CA2474424C (en) 2013-03-26

Similar Documents

Publication Publication Date Title
CN100548993C (zh) 缬沙坦的盐
CN100413852C (zh) 缬沙坦的盐
AU2001289672A1 (en) Valsartan salts
AU2009201898B2 (en) Valsartan salts
HK1139681B (en) Salts of valsartan
AU2007205815A1 (en) Salts of valsartan
HK1055963B (en) Valsartan salts

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Address before: Basel, Switzerland

Patentee before: Novartis AG

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20091014